TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Polypeptide Laboratories Holding (PPL) AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
157,812
|
156,255
|
119,067 |
| Financial expenses |
15,987
|
11,306
|
3,916 |
| Earnings before taxes |
-30,211
|
-29,931
|
-19,028 |
| EBITDA |
-24,650
|
-51,465
|
-15,074 |
| Total assets |
424,555
|
395,228
|
269,039 |
| Current assets |
115,880
|
134,866
|
52,178 |
| Current liabilities |
181,961
|
118,001
|
76,378 |
| Equity capital |
28,354
|
37,341
|
49,217 |
| - share capital |
18
|
18
|
18 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
6.7%
|
9.4%
|
18.3% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
-19.1%
|
-19.2%
|
-16.0% |
| Return on assets (ROA) |
-3.4%
|
-4.7%
|
-5.6% |
| Current ratio |
63.7%
|
114.3%
|
68.3% |
| Return on equity (ROE) |
-106.5%
|
-80.2%
|
-38.7% |
| Change turnover |
6,869
|
36,841
|
38,896 |
| Change turnover % |
5%
|
31%
|
49% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.